TipRanks on MSN

Legend Biotech price target raised to $75 from $66 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Legend Biotech (LEGN) to $75 from $66 and keeps an Overweight rating on the shares. Legend ...

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, today announced the official opening and ...
TipRanks on MSN

Legend Biotech price target lowered to $90 from $94 at Barclays

Barclays analyst Gena Wang lowered the firm’s price target on Legend Biotech (LEGN) to $90 from $94 and keeps an Overweight rating on the shares following the Q3 report. Meet Your ETF AI Analyst ...